

SWORD AND SHIELD PHARMA LIMITED

CIN: L24231GJ1995PLC024809


Registered Office: 55, World Business House, Near Parimal Garden, Ambawadi, Ahmedabad - 380 006.

Website: www.swordnshieldpharma.com

Contact: +91 98250 79759

Statement of Audited Financial Results for the quarter and year ended March 31, 2018

Particulars	Quarter Ended			Year Ended	
	31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017
A Date of start of reporting period	01/01/2018	01/10/2017	01/01/2017	01/04/2017	01/04/2016
B Date of end of reporting period	31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017
C Whether results are audited or unaudited	Audited	Unaudited	Audited	Audited	Audited
D Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone
I Revenue From Operations					
Net sales or Revenue from Operations	-	51,800.00	7,10,949.00	2,89,462.00	6,85,768.00
II Other Income	2,300.00	2,060.00	17,890.00	5,785.00	17,794.00
III Total Income (I+II)	2,300.00	53,860.00	7,28,839.00	2,95,247.00	7,03,562.00
IV Expenses					
(a) Cost of materials consumed	-	-	-	-	-
(b) Purchases of stock-in-trade	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
(d) Employee benefit expense	1,26,000.00	1,21,232.00	93,630.00	4,53,943.00	4,21,833.00
(e) Finance Costs	-	-	-	4,619.00	641.00
(f) Depreciation and amortisation expense	-	-	-	-	-
(g) Other Expenses	29,846.00	33,668.00	2,23,519.45	3,98,686.00	4,00,790.95
Legal & Professional Fees	-	59,000.00	64,350.00	8,08,049.90	-
Payment to Auditors	1,20,000.00	-	1,09,250.00	-	-
Kasar & Write Off	71,065.00	-	-	-	-
Income Tax Expense	64,605.00	-	-	-	-
Stock Exchange Fees/ Listing & Reinstatement Fees/Custodian Fees	-	1,84,841.00	-	2,36,593.00	25,41,900.00
Total expenses (IV)	4,11,516.00	3,98,741.00	3,17,149.45	19,01,890.90	33,58,764.95
V Profit/(loss) before exceptional items and tax (III-IV)	(4,09,216.00)	(3,44,881.00)	4,11,689.55	(16,06,643.90)	(24,55,122.95)
VI Exceptional Items	-	-	-	-	-
VII Profit (loss) after exceptional items and before Tax (V-VI)	(4,09,216.00)	(3,44,881.00)	4,11,689.55	(16,06,643.90)	(24,55,122.95)
VIII Tax Expense	-	-	-	-	-
(a) Current Tax	-	-	-	-	-
(b) (Less):- MAT Credit	-	-	-	-	-
(c) Current Tax Expense Relating to Prior years	-	-	-	-	-
(d) Deferred Tax (Asset)/Liabilities	-	-	-	-	-
IX Profit (Loss) for the period from continuing operations (VII-VIII)	(4,09,216.00)	(3,44,881.00)	4,11,689.55	(16,06,643.90)	(24,55,122.95)
X Profit/(loss) from discontinued operations	-	-	-	-	-
XI Tax expenses of discontinued operations	-	-	-	-	-
XII Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII A Profit(Loss) For Period Before Minority Interest	(4,09,216.00)	(3,44,881.00)	4,11,689.55	(16,06,643.90)	(24,55,122.95)
XIII B Share Of Profit / Loss of Associates and joint ventures accounted for using equity method	-	-	-	-	-
XIII C Profit/Loss Of Minority Interest	-	-	-	-	-
XIV Profit (Loss) for the period (XIII A + XIII B + XIII C)	(4,09,216.00)	(3,44,881.00)	4,11,689.55	(16,06,643.90)	(24,55,122.95)
XV Other Comprehensive Income					
a. i). Items that will not be reclassified to profit or loss	-	-	-	-	-
ii). income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
b i). Item that will be reclassified to profit or loss	-	-	-	-	-
ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income	-	-	-	-	-
XVI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV)	(4,09,216.00)	(3,44,881.00)	4,11,689.55	(16,06,643.90)	(24,55,122.95)



SWORD AND SHIELD PHARMA LIMITED

CIN: L24231GJ1995PLC024809

Registered Office: 55, World Business House, Near Parimal Garden, Ambawadi, Ahmedabad - 380 006.

Website: www.swordnshieldpharma.com

Contact: +91 98250 79759

Statement of Audited Financial Results for the quarter and year ended March 31, 2018

Particulars	Quarter Ended			Year Ended	
	31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017
A Date of start of reporting period	01/01/2018	01/10/2017	01/01/2017	01/04/2017	01/04/2016
B Date of end of reporting period	31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017
C Whether results are audited or unaudited	Audited	Unaudited	Audited	Audited	Audited
D Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone
XVII Details of equity share capital					
Paid-up equity share capital	5,15,06,000.00	5,15,06,000.00	46619170.00	5,15,06,000.00	46619170.00
Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX Earnings per share					
(a) Earnings per share (not annualised for quarter ended)					
Basic earnings (loss) per share from continuing operation	(0.079)	(0.067)	0.088	(0.322)	(0.526)
Diluted earnings (loss) per share from continuing operation	(0.079)	(0.067)	0.088	(0.322)	(0.526)
(b) Earnings per share (not annualised for quarter ended)					
Basic earnings (loss) per share from discontinued operation	-	-	-	-	-
Diluted earnings (loss) per share from discontinued operation	-	-	-	-	-
(c) Earnings per share (not annualised for quarter ended)					
Basic earnings (loss) per share from continuing and discontinued operations	(0.079)	(0.067)	0.088	(0.322)	(0.526)
Diluted earnings (loss) per share continuing and discontinued operations	(0.079)	(0.067)	0.088	(0.322)	(0.526)

Notes on Financial Results:-

- 1 The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on May 30, 2018.
- 2 The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1st April 2017, the Company has for the first time adopted Ind AS with a transition date of 1st April 2017.
- 3 The format of the above results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with the requirements of SEBI's Circular dated 5th July, 2016, Ind AS and Schedule III [Division II] to the Companies Act 2013.
- 4 The Statutory Auditors of the Company have carried out a Audit of the above results as per Regulation 33 of the SEBI [Listing Obligation and Disclosure Requirements] Regulations, 2015. The corresponding Ind AS compliant figures of the previous year have not been subjected to audit. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its results.
- 5 Previous year's/period's figure have been regrouped/rearranged wherever necessary.

For, Sword & Shield Pharma Limited



Pravinbhai Patel
Managing Director,
DIN: 01877446

Date :- May 30, 2018
Place: Pennsylvania

SWORD AND SHIELD PHARMA LIMITED

CIN: L24231GJ1995PLC024809

Registered Office: 55, World Business House, Near Parimal Garden, Ambawadi, Ahmedabad - 380 006.

Website: www.swordnshieldpharma.com

Contact: +91 98250 79759

Statement of Audited Assets and Liabilities as at March 31, 2018

Particulars		Year Ended	
		31/03/2018	31/03/2017
A	Date of start of reporting period	01/04/2017	01/04/2016
B	Date of end of reporting period	31/03/2018	31/03/2017
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
(ii)	Trade payables	-	-
(iii)	Other financial liabilities (other than those specified in item (b), to be	-	-
b)	Provisions	-	-
c)	Deferred tax liabilities (Net)	-	-
d)	Deferred government grants (non current)	-	-
e)	Other non-current liabilities	-	-
2)	Current liabilities		
a)	Financial Liabilities	-	-
(i)	Borrowings	-	-
(ii)	Trade payables	50,224.00	-
(iii)	Other financial liabilities (other than those specified in item (c)	-	-
b)	Other current liabilities	1,63,824.00	4,51,543.00
c)	Provisions	-	-
d)	Current Tax Liabilities (Net)	-	-
e)	Deferred government grants (non current)	-	-
3	Liabilities directly associated with assets in disposal group classified as held for sale	-	-
4	Regulatory deferral account credit balances and related deferred tax liabilities	-	-
Total Liabilities		21,26,285.55	19,66,594.45

For, Sword & Shield Pharma Limited

Date :- May 30, 2018

Place:- Pennsylvania

